Eli Lilly Acquires Disarm and Its SARM1 Inhibitors for Preventing Axonal Degeneration

[jd58]

“The scientific team at Disarm discovered an important and highly promising approach to combat axonal degeneration. We will move quickly to develop their SARM1 inhibitors into potential medicines for peripheral neuropathy and neurological diseases, such as ALS and multiple sclerosis,” Mark Mintun, MD, vice president of pain and neurodegeneration research at Lilly, said in a press release.

https://alsnewstoday.com/news-posts/...aign=OneSignal

[Lynne K]

Thanks JD5, good news but needs testing so likely won’t be available as a treatment for years. Lynne